Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 3/20 | 0.46 |
| ▸ | MMP9 | P14780 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1937359 | 0.87 | GAA (0.51) | GAAELANEALDH1A1MEN1KMT2A | |
| SCHEMBL11360473 | 0.81 | ALDH1A1 (0.47) | GAAALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL7265100 | 0.80 | ALDH1A1 (0.56) | GAAMMP9ALDH1A1MMEMEN1 | |
| SCHEMBL7272751 | 0.80 | ALDH1A1 (0.56) | GAAMMP9ALDH1A1MMEMEN1 | |
| SCHEMBL11726171 | 0.79 | LMNA (0.47) | GAAALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL12478036 | 0.79 | LMNA (0.47) | GAAALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL29132822 | 0.79 | KDM4E (0.57) | GAAMMP9ALDH1A1MEN1KMT2A | |
| SCHEMBL29132823 | 0.79 | KDM4E (0.57) | GAAMMP9ALDH1A1MEN1KMT2A | |
| SCHEMBL30660068 | 0.79 | KDM4E (0.57) | GAAMMP9ALDH1A1MEN1KMT2A | |
| SCHEMBL8624980 | 0.76 | METAP2 (0.41) | GAAMMP9ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170239216-A1 | SMALL MOLECULE INHIBITORS OF N-TERMINUS ACTIVATION OF THE ANDROGEN RECEPTOR | THE UNITED STATES GOVERNMENT | 2017-08-24 | — | — | US | disclosed |
| US-9487479-B2 | Small molecule inhibitors of N-terminus activation of the androgen receptor | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-11-08 | — | — | US | disclosed |
| EP-2331501-B1 | SMALL MOLECULE INHIBITORS OF N-TERMINUS ACTIVATION OF THE ANDROGEN RECEPTOR | BRITISH COLUMBIA CANCER AGENCY (CA) | 2016-07-20 | — | — | EP | disclosed |
| US-20110230539-A1 | Small Molecule Inhibitors of N-Terminus Activation of the Androgen Receptor | THE UNITED STATES GOVERNMENT | 2011-09-22 | — | — | US | disclosed |
| CN-102131775-A | Small molecule inhibitors of N-terminus activation of the androgen receptor | BRITISH COLUMBIA CANCER AGENCY | 2011-07-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239216-A1 | SMALL MOLECULE INHIBITORS OF N-TERMINUS ACTIVATION OF THE ANDROGEN RECEPTOR | AR, KLK3, NR5A1 | GAA 3268/4885ELANE 1145/4885MMP1 3039/4885 |
| US-20110230539-A1 | Small Molecule Inhibitors of N-Terminus Activation of the Androgen Receptor | AR, KLK3, NR5A1 | GAA 3268/4885ELANE 1145/4885MMP1 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.